CureVac (CVAC) to Release Earnings on Thursday

Key Points

• CureVac (CVAC) is set to release its Q2 2025 earnings results on August 21st, with analysts projecting a loss of ($0.15) per share and revenue of $4.27 million.
• In its last earnings announcement, the company reported a loss of ($0.24) per share and significantly missed revenue expectations, raising concerns about its financial performance.
• Following recent adjustments, the consensus rating for CureVac's stock is "Hold" with an average price target of $6.83 after several analysts revised their ratings and targets downward.

CureVac (NASDAQ:CVAC - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 21st. Analysts expect CureVac to post earnings of ($0.15) per share and revenue of $4.27 million for the quarter.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 30.89% and a net margin of 35.44%. The business had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Stock Up 0.5%

Shares of NASDAQ:CVAC opened at $5.50 on Thursday. CureVac has a 12 month low of $2.37 and a 12 month high of $5.72. The company's 50-day moving average price is $5.33 and its two-hundred day moving average price is $4.07. The company has a quick ratio of 7.64, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.23 billion, a P/E ratio of 5.98 and a beta of 2.53.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CVAC shares. Jefferies Financial Group restated a "hold" rating and set a $5.00 target price (down previously from $7.00) on shares of CureVac in a research report on Friday, June 13th. Citigroup lowered CureVac to a "market perform" rating in a research report on Thursday, June 12th. UBS Group lowered CureVac from a "strong-buy" rating to a "neutral" rating and reduced their price target for the stock from $12.00 to $5.50 in a research report on Thursday, June 26th. JMP Securities restated a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th. Finally, Citizens Jmp lowered CureVac from a "strong-buy" rating to a "hold" rating in a research report on Thursday, June 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, CureVac presently has a consensus rating of "Hold" and an average price target of $6.83.

Institutional Trading of CureVac

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gabelli Funds LLC bought a new position in CureVac during the second quarter worth $130,000. Amundi boosted its position in CureVac by 96.9% during the second quarter. Amundi now owns 136,796 shares of the company's stock worth $739,000 after purchasing an additional 67,310 shares during the period. Legal & General Group Plc boosted its position in CureVac by 7.3% during the second quarter. Legal & General Group Plc now owns 123,250 shares of the company's stock worth $661,000 after purchasing an additional 8,411 shares during the period. JPMorgan Chase & Co. bought a new position in CureVac during the second quarter worth $1,705,000. Finally, Geode Capital Management LLC boosted its position in CureVac by 12.5% during the second quarter. Geode Capital Management LLC now owns 246,203 shares of the company's stock worth $1,337,000 after purchasing an additional 27,377 shares during the period. 17.26% of the stock is owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.